Not yet recruitingPHASE2INTERVENTIONAL

Dynamic 82-Rb Positron Emission Tomography (PET) for the Grading of KIDney Carcinoma

This study is exploring a new scanning method to help doctors understand kidney cancer better before surgery. We are focusing on a type of kidney cancer called renal cell carcinoma. Currently, a small sample (biopsy) might not always show how aggressive the cancer truly is, which can make treatment planning difficult. This study uses a special scan called a PET scan, where a substance called 82-Rb is injected. We want to see if the way this substance is taken up by the tumour on the scan can accurately predict how aggressive the cancer is when it's later examined in detail. This could help doctors make more informed decisions about treatment and give patients the best possible care without needing a more invasive procedure to assess aggressiveness.

At a glance

Status

Not yet recruiting

Phase

PHASE2

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrolment target

Start

01 Jan 2026

Estimated completion

01 Jan 2028

Renal Cell Carcinoma

What is this study about?

This research is looking into a new way to assess kidney cancer before surgery. Understanding how aggressive a kidney tumour is before an operation is really important for doctors to plan the best treatment. At the moment, doctors might take a small sample (a biopsy) from the tumour, but sometimes this can't fully show how aggressive the cancer is, meaning the exact nature of the tumour might be underestimated.

This study uses a type of scan called a PET scan. During the scan, a small amount of a special substance, 82-Rb, is injected into your bloodstream. This substance is similar to potassium and is taken up by certain cells, including those in the kidneys. Doctors want to see if the amount of 82-Rb taken up by the kidney tumour on the scan can show if the cancer is less aggressive (low-grade) or more aggressive (high-grade). This could provide a clearer picture of the cancer's behaviour.

The main goal is to see if this PET scan with 82-Rb can accurately predict the aggressiveness of kidney cancer. If successful, this method could help doctors make more precise decisions about your care before surgery, potentially leading to better outcomes. Using this scan might offer a less invasive way to get crucial information about the tumour's aggressiveness.

Key takeaways

This study aims to find a better way to assess kidney cancer aggressiveness before surgery.
It uses a PET scan with a special tracer called 82-Rb.
The goal is to see if the scan can tell the difference between less aggressive and more aggressive tumours.
This could help doctors make more precise treatment plans for patients.
Participation involves scans, blood tests, and follow-up after surgery.

Who may be eligible?

To be considered for this study, you need to be at least 18 years old and willing to give your informed consent. You also need to be part of the French Social Security system. We are looking for patients who either have a strong suspicion of kidney cancer (renal cell carcinoma) or have been diagnosed with it and are planning to have surgery.

Your kidney tumour should be between 2 and 7 centimetres in size, and look a certain way on imaging scans, suggesting it's a specific type of kidney cancer. You must also be able to attend all scheduled appointments and follow the study instructions carefully.

There are some reasons why you might not be able to join. For example, if you are pregnant or breastfeeding, if you are under legal protection, or if a PET-CT scan or the 82-Rb injection isn't suitable for you. We also can't include people with certain health conditions affecting their kidneys, specific types of kidney cysts, or hereditary forms of kidney cancer. If your tumour is highly suspected of having spread outside the kidney, you also wouldn't be able to participate.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Am I 18 years or older?
Do I have kidney cancer or a strong suspicion of it, and am I having surgery?
Is my kidney tumour between 2 and 7 cm in size?
Am I able to attend all scheduled study appointments?
Am I not pregnant or breastfeeding?
Do I not have certain other kidney conditions or hereditary forms of kidney cancer?

Answer every question to see your result.

What does participation involve?

If you decide to take part in this study, you will have several scheduled visits. These visits will involve various tests and procedures, including a PET scan with the 82-Rb injection. This injection is given into your vein. The study aims to follow how the 82-Rb is taken up by your tumour over time during the scan itself. You will also have standard laboratory tests, and there will be follow-up appointments after your surgery. There are no other medications specifically for the study. The total duration of your participation, from your initial scans to your follow-up after surgery, will be explained in detail by the study team.

Potential risks and benefits

Taking part in this study might offer the benefit of a more detailed understanding of your kidney tumour before surgery, which could help your doctors fine-tune your treatment plan. However, as with any medical procedure, there are potential risks, such as those associated with the PET scan itself (like exposure to a small amount of radiation, similar to other diagnostic scans) and the 82-Rb injection (which might cause a very brief sensation or, rarely, an allergic reaction). You will be closely monitored by medical staff. Remember, your participation is completely voluntary, and you have the right to withdraw from the study at any time without affecting your medical care.

Locations (2)

AP-HP - hôpital européen Georges-Pompidou
Verified postcode
Paris, France
AP-HP - hôpital européen Georges-Pompidou
Verified postcode
Paris, France

Common questions

What is a PET scan?

A PET scan is a type of imaging test that helps doctors see how your organs and tissues are working. It uses a small amount of a special substance to highlight areas of interest in your body.

What is 82-Rb?

82-Rb is a special, safe substance that's injected during the PET scan. It helps doctors see how much of it is taken up by your kidney tumour, which might give clues about its aggressiveness.

Will taking part in this study change my kidney cancer treatment?

The information gathered will help your doctors understand your tumour better. It may help them make more informed decisions about your treatment *before* surgery, but it won't replace standard care.

Are there any side effects from the 82-Rb injection?

Most people tolerate the 82-Rb injection well. As with any injection, you might feel a brief sting. Serious reactions are very rare, but the study team will discuss all potential risks with you.

How long will I be involved in the study?

The study involves a few visits, including the scan, and some follow-up after your planned surgery. The study team will tell you the exact timeline during your consent process.

How to find out more

Touria AL AAMRI

touria.el-aamri@aphp.fr +33 1 40 27 18 48 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.